119 related articles for article (PubMed ID: 35113575)
1. Preclinical Validation of Tumor-Penetrating and Interfering Peptides against Chronic Lymphocytic Leukemia.
Simón-Gracia L; Loisel S; Sidorenko V; Scodeller P; Parizot C; Savier E; Haute T; Teesalu T; Rebollo A
Mol Pharm; 2022 Mar; 19(3):895-903. PubMed ID: 35113575
[TBL] [Abstract][Full Text] [Related]
2. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans.
Martinez-Torres AC; Quiney C; Attout T; Boullet H; Herbi L; Vela L; Barbier S; Chateau D; Chapiro E; Nguyen-Khac F; Davi F; Le Garff-Tavernier M; Moumné R; Sarfati M; Karoyan P; Merle-Béral H; Launay P; Susin SA
PLoS Med; 2015 Mar; 12(3):e1001796. PubMed ID: 25734483
[TBL] [Abstract][Full Text] [Related]
3. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
Christensen DJ; Chen Y; Oddo J; Matta KM; Neil J; Davis ED; Volkheimer AD; Lanasa MC; Friedman DR; Goodman BK; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Vitek MP; Weinberg JB
Blood; 2011 Oct; 118(15):4150-8. PubMed ID: 21844565
[TBL] [Abstract][Full Text] [Related]
4. Cell penetrating peptides as a therapeutic strategy in chronic lymphocytic leukemia.
Arrouss I; Decaudin D; Choquet S; Azar N; Parizot C; Zini JM; Nemati F; Rebollo A
Protein Pept Lett; 2015; 22(6):539-46. PubMed ID: 25687226
[TBL] [Abstract][Full Text] [Related]
5. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumoral Effect of a Cell Penetrating and Interfering Peptide Targeting PP2A/SET Interaction.
Andrini L; Marin GH; Inda AM; Bruzzoni-Giovanelli H; Garcia M; Errecalde J; Rebollo A
Folia Med (Plovdiv); 2020 Mar; 62(1):31-36. PubMed ID: 32337908
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic.
Ghiotto F; Fais F; Tenca C; Tomati V; Morabito F; Casciaro S; Mumot A; Zoppoli G; Ciccone E; Parodi S; Bruno S
Cancer Biol Ther; 2009 Feb; 8(3):263-71. PubMed ID: 19164937
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy.
Arrouss I; Nemati F; Roncal F; Wislez M; Dorgham K; Vallerand D; Rabbe N; Karboul N; Carlotti F; Bravo J; Mazier D; Decaudin D; Rebollo A
PLoS One; 2013; 8(4):e60816. PubMed ID: 23637769
[TBL] [Abstract][Full Text] [Related]
9. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
[TBL] [Abstract][Full Text] [Related]
10. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
Pramil E; Herbi Bastian L; Denèfle T; Nemati F; Xiao M; Lardé E; Maloum K; Roos-Weil D; Chapiro E; Le Garff-Tavernier M; Davi F; Decaudin D; Sarfati M; Nguyen-Khac F; Merle-Béral H; Karoyan P; Susin SA
Blood Adv; 2019 Oct; 3(20):2920-2933. PubMed ID: 31648314
[TBL] [Abstract][Full Text] [Related]
11. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
[TBL] [Abstract][Full Text] [Related]
13. Gold Cluster Capped with a BCL-2 Antagonistic Peptide Exerts Synergistic Antitumor Activity in Chronic Lymphocytic Leukemia Cells.
Yao Y; Lu C; Gao L; Cao K; Yuan H; Zhang X; Gao X; Yuan Q
ACS Appl Mater Interfaces; 2021 May; 13(18):21108-21118. PubMed ID: 33942607
[TBL] [Abstract][Full Text] [Related]
14. Selective Anticancer Activity of Acacetin Against Chronic Lymphocytic Leukemia Using Both In Vivo and In Vitro Methods: Key Role of Oxidative Stress and Cancerous Mitochondria.
Salimi A; Roudkenar MH; Sadeghi L; Mohseni A; Seydi E; Pirahmadi N; Pourahmad J
Nutr Cancer; 2016; 68(8):1404-1416. PubMed ID: 27779444
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.
Severin F; Urbani A; Varanita T; Bachmann M; Azzolini M; Martini V; Pizzi M; Tos APD; Frezzato F; Mattarei A; Ghia P; Bertilaccio MTS; Gulbins E; Paradisi C; Zoratti M; Semenzato GC; Leanza L; Trentin L; Szabò I
J Exp Clin Cancer Res; 2022 Feb; 41(1):64. PubMed ID: 35172855
[TBL] [Abstract][Full Text] [Related]
16. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia.
Prezma T; Shteinfer A; Admoni L; Raviv Z; Sela I; Levi I; Shoshan-Barmatz V
Cell Death Dis; 2013 Sep; 4(9):e809. PubMed ID: 24052077
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.
Martinez Marignac VL; Smith S; Toban N; Bazile M; Aloyz R
Oncotarget; 2013 Dec; 4(12):2550-66. PubMed ID: 24334291
[TBL] [Abstract][Full Text] [Related]
18. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
19. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
Lucas DM; Edwards RB; Lozanski G; West DA; Shin JD; Vargo MA; Davis ME; Rozewski DM; Johnson AJ; Su BN; Goettl VM; Heerema NA; Lin TS; Lehman A; Zhang X; Jarjoura D; Newman DJ; Byrd JC; Kinghorn AD; Grever MR
Blood; 2009 May; 113(19):4656-66. PubMed ID: 19190247
[TBL] [Abstract][Full Text] [Related]
20. Role of decreased production of interleukin-10 and interferon-gamma in spontaneous apoptosis of B-chronic lymphocytic leukemia lymphocytes in vitro.
Djurdjevic P; Zelen I; Ristic P; Baskic D; Popovic S; Arsenijevic N
Arch Med Res; 2009 Jul; 40(5):357-63. PubMed ID: 19766898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
